CompletedPhase 4

Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia

United States16 participantsStarted 2003-04

Plain-language summary

This study uses a computerized method of musical instrument digital interface (MIDI) quantification of performance before and after treatment with botulinum toxin type B (Myobloc ®, Solstice Neurosciences). Myobloc is a purified and diluted form of botulinum toxin used medically to relax unwanted muscle spasms and movements. The aim of the study is to determine the feasibility of quantifying change in performance following treatment.

Who can participate

Age range25 Years – 69 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Focal, task-specific dystonia clinically determined to be the result of a high level of musical skill and intensive performance history Exclusion Criteria: * Neurological disorders other than dystonia * Patients who are clinically depressed, demented or otherwise unable to perform appropriately or sit through 1 hour of testing * Patients who have undergone pallidotomy, thalamotomy or deep brain stimulator implantations * Patients who have who recently have taken medications with extrapyramidal or tremorogenic side effects

What they're measuring

Note Errors (Related to Errors in Duration)

Timeframe: Baseline and 6 weeks post-injection

Note Errors (Related to Errors in Loudness)

Timeframe: Baseline and 6 weeks post-injection

Trial details

NCT IDNCT00208091

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-05

Results submitted2013-08-22

View on ClinicalTrials.gov More Focal Dystonia trials